Sonnet BioTherapeutics Holdings Shares Outstanding 2006-2021 | SONN

Sonnet BioTherapeutics Holdings shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Sonnet BioTherapeutics Holdings Annual Shares Outstanding
(Millions of Shares)
2020 9
2019 0
2019 5
2018 0
2017 0
2016 0
2015 0
2014 0
2013 0
2012 0
2012
2011 0
2011
2010 0
2009 0
2008 0
2007 0
2006
2005
Sonnet BioTherapeutics Holdings Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 23
2021-03-31 19
2020-12-31 17
2020-09-30 9
2020-06-30 11
2020-03-31 6
2019-12-31
2019-09-30 0
2019-06-30 5
2019-03-31 0
2018-12-31
2018-09-30 0
2018-06-30 0
2018-03-31 0
2017-12-31
2017-09-30 0
2017-06-30 0
2017-03-31 0
2016-12-31
2016-09-30 0
2016-06-30 0
2016-03-31 0
2015-12-31
2015-09-30 0
2015-06-30 0
2015-03-31 0
2014-12-31
2014-09-30 0
2014-06-30 0
2014-03-31 0
2013-12-31
2013-09-30 0
2013-06-30 0
2013-03-31 0
2012-12-31
2012-09-30 0
2012-06-30 0
2012-03-31 0
2011-12-31
2011-09-30 0
2011-06-30 0
2011-03-31 0
2010-12-31
2010-09-30 0
2010-06-30 0
2010-03-31 0
2009-12-31
2009-09-30
2009-06-30
2009-03-31
2008-12-31
2008-09-30
2008-06-30
2008-03-31
2007-12-31
2007-09-30
2007-06-30
2007-03-31
2006-12-31
2006-09-30
2006-06-30
2006-03-31
2005-12-31
2005-09-30
2005-06-30
2005-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.015B $0.041B
Sonnet BioTherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for biologic drugs of single or bispecific action. Sonnet BioTherapeutics Holdings Inc., formerly known as Chanticleer Holdings Inc., is based in PRINCETON, N.J.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71